Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Exercise Training Program.
- Who it may be relevant to
- Registry conditions: Breast Cancer, Breast Cancer Female. Basic parameters: 18 years — 59 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this study is to learn more about how exercise might lower the risk of developing breast cancer in women with dense breast tissue by studying changes that occur in breast tissue and blood as a result of participating in an exercise program. The names of the study groups in this study are: * Exercise Training Group * Waitlist Control Group
Detailed description
The goal of this study is to learn more about how exercise might lower the risk of developing breast cancer by studying changes that occur in breast tissue and blood as a result of participating in an exercise program. Participants will be placed into one of two study groups: Exercise Training Group vs. Waitlist Control Group. Randomization means that a participant is put into a group by chance.
The research study procedures include screening for eligibility and baseline and end of study assessments which include: breast biopsies, assessment of physical activity habits, aerobic and strength testing, blood draws and questionnaires.
Participants randomized to the exercise group will be expected to participate in exercise sessions throughout the study. They will also be asked to complete logs of their activity.
Participants will be in this research study for up to 16 weeks.
It is expected that 46 women will take part in this study.
The Breast Cancer Research Foundation is supporting this research study by providing funding.
Interventions
- Behavioral Exercise Training Program
A 12-week aerobic and resistance-training exercise intervention with a certified exercise trainer in person or virtually. FitBit activity tracker, resistance bands, hand weights, and stationary bike will be provided to participants. Hand weights will be returned at end of study.
Primary outcome measures
- Change in Irisin in Exercise Group [Time frame: At baseline, within 2 hours of 1st exercise session, and at week 12, up to 16 weeks]
- Change in Irisin in Control Group [Time frame: At baseline and week 12, up to 16 weeks]
Secondary outcome measures (12)
- Change in Tissue Markers in Exercise Group [Time frame: At baseline and week 12, up to 16 weeks]
- Change in Tissue Markers in Control Group [Time frame: At baseline and week 12, up to 16 weeks]
- Change in Biomarkers in Exercise Group - Meso scale [Time frame: At baseline and week 12, up to 16 weeks]
- Change in Biomarkers in Exercise Group - Mass cytometry [Time frame: At baseline and week 12, up to 16 weeks]
- Change in Biomarkers in Control Group - Meso Scale [Time frame: At baseline and week 12, up to 16 weeks]
- Change in Biomarkers in Control Group - Mass cytometry [Time frame: At baseline and week 12, up to 16 weeks]
- Change in Participant Weight in Exercise Group [Time frame: At baseline and week 12, up to 16 weeks]
- Change in Participant Weight in Control Group [Time frame: At baseline and week 12, up to 16 weeks]
- Change in Cardiorespiratory Fitness in Exercise Group [Time frame: At baseline and week 12, up to 16 weeks]
- Change in Cardiorespiratory Fitness in Control Group [Time frame: At baseline and week 12, up to 16 weeks]
- 10-Repetition Max Test in Exercise Group [Time frame: At baseline and week 12, up to 16 weeks]
- 10-Repetition Max Test in Control Group [Time frame: At baseline and week 12, up to 16 weeks]
Eligibility criteria
Inclusion criteria
- Women aged 18-59
- Heterogeneously dense/extremely dense (BIRADS 3 or 4) breast tissue on mammogram within the past 12 months
- Physically inactive; engaging in <60 minutes of moderate or vigorous intensity exercise per week, as assessed by Godin Leisure Time screener
- Not pregnant or breastfeeding
- English speaking and able to read English. Investigators are only enrolling English-speaking participants to this study at this time due to the fact that investigators currently only have English-speaking exercise trainers with the proper qualifications to conduct the exercise training
- Written informed consent prior to any study-related procedures
Exclusion criteria
- Self-reported inability to walk 2 blocks (at any pace)
- Prior history of breast cancer; prior DCIS is allowable as long as participant is not taking endocrine therapy and has at least 1 breast that has not been irradiated
- On oral or implantable hormonal contraceptives, postmenopausal hormone replacement therapy, a selective estrogen receptor modulator or an aromatase inhibitor; Mirena or other IUD is acceptable
- Consistent strength training in the past 3 months
- Use of weightloss drugs
- Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate exercise. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility
- Psychiatric disorders or conditions that would preclude participation in the study intervention (e.g. untreated major depression or psychosis, substance abuse, severe personality disorder)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
United States · 2 centers
- Brigham and Women's Hospital — Boston
- Dana Farber Cancer Institute — Boston
Identifiers
NCT: NCT06322888 · 23-676